Clinical Trials
22 trialsNCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT05228470 2026-01-06
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
Phase 2 Completed
NCT04830046 2025-11-26
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Massachusetts General Hospital
Completed
NCT05451212 2025-11-10
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
Cabaletta Bio
Phase 1 Completed
NCT03744676 2025-02-27
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
Phase 2 Completed
NCT02112526 2024-12-20
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 1 Completed
NCT01183949 2024-08-02
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01063907 2024-04-25
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT02658968 2024-01-16
Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
Nordic Nanovector
Phase 1 Completed
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT05917184 2023-06-23
ADAPT-teleMG
Yale University
Completed
NCT04445402 2023-05-03
Pediatrics HOT COVID-19 Database in NY Tristate
Columbia University
Completed
NCT04977739 2022-08-22
Research on the Application and Mechanism of New Biological Probes in Biomedicine
Nanfang Hospital, Southern Medical University
Completed
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT00772486 2021-09-22
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
Memgen, Inc.
Phase 1 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01990534 2021-04-09
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Takeda
Phase 4 Completed
NCT02799147 2020-11-23
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
St. Petersburg State Pavlov Medical University
Phase 1/2 Completed
NCT02294552 2018-01-16
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
St. Petersburg State Pavlov Medical University
Phase 2 Completed
NCT00000591 2016-04-15
T-Cell Depletion in Unrelated Donor Marrow Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00783588 2008-10-31
A Phase I Extension Trial of Repeated Infusions of ISF35
Memgen, Inc.
Phase 1 Completed
NCT00779883 2008-10-24
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Memgen, Inc.
Phase 1 Completed